Pages that link to "Q48268803"

The following pages link to Potential role of muscarinic receptors in schizophrenia (Q48268803):

Displaying 25 items.

• Novel interaction between the M4 muscarinic acetylcholine receptor and elongation factor 1A2 (Q28202533) (← links)
• Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates (Q28546449) (← links)
• Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice (Q28587873) (← links)
• F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms. (Q30494674) (← links)
• Regulation of synaptic plasticity in a schizophrenia model (Q33948009) (← links)
• Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. (Q34212336) (← links)
• SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. (Q34561031) (← links)
• Evaluation of N-desmethylclozapine as a potential antipsychotic--preclinical studies (Q34590400) (← links)
• Role of the cholinergic muscarinic system in bipolar disorder and related mechanism of action of antipsychotic agents (Q34622385) (← links)
• Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system (Q35098516) (← links)
• Rat modeling for GABA defects in schizophrenia (Q36686912) (← links)
• Cholinergic circuits and signaling in the pathophysiology of schizophrenia (Q36756379) (← links)
• Acetylcholine-dopamine interactions in the pathophysiology and treatment of CNS disorders. (Q37725116) (← links)
• Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review (Q37920918) (← links)
• Pharmacological approaches to the management of schizophrenia: 10 years on. (Q38101540) (← links)
• The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex (Q43582607) (← links)
• The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance (Q43601610) (← links)
• Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor. (Q43662847) (← links)
• Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine‐induced seizure activity (Q44416460) (← links)
• Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera (Q44733700) (← links)
• Decreased amphetamine-induced locomotion and improved latent inhibition in mice mutant for the M5 muscarinic receptor gene found in the human 15q schizophrenia region. (Q44949323) (← links)
• Chronic phencyclidine (PCP)-induced modulation of muscarinic receptor mRNAs in rat brain : Impact of antipsychotic drug treatment (Q45331619) (← links)
• Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol (Q46354616) (← links)
• Elongation factor 1A family regulates the recycling of the M4 muscarinic acetylcholine receptor (Q48469789) (← links)
• Muscarinic receptor agonists decrease cocaine self-administration rates in drug-naive mice. (Q51384162) (← links)